The BMJ’s stance on collaboration with industryBMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f6467 (Published 29 October 2013) Cite this as: BMJ 2013;347:f6467
- Fiona Godlee, editor in chief1
- 1BMJ, BMA House, London WC1H 9JR, UK
Goldacre asks how so many health organisations signed misleading guidelines for collaboration with the drug industry.1 Let me explain how this happened at the BMJ.
We asked the Association of the British Pharmaceutical Industry (ABPI) to sponsor two co-branded seminars—on access to clinical trial data and the role of industry in medical education. Working in partnership with a commercial sponsor was new for the BMJ. Both meetings went well, with lively debate from an invited audience.
The BMJ was not a member of the Ethical Standards in Health and Life Sciences Group (ESHLSG), had published an …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial